Catalyst Wire Dossier Catalyst Wire Dossier

SYFOVRE

pegcetacoplan · Apellis Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for SYFOVRE, covering 2023-02-17 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

See pricing